{"analyses":[{"ciLowerLimit":"3.0","ciPctValue":"95","ciUpperLimit":"37.2","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0246","pValueComment":"Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites).\n\nStatistically significant at pre-specified alpha of 20%.","paramType":"Difference in Percentage of Participants","paramValue":"20.1","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"8.9","ciNumSides":"TWO_SIDED","ciPctValue":"80","ciUpperLimit":"31.3","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0246","pValueComment":"Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites).\n\nStatistically significant at pre-specified alpha of 20%.","paramType":"Difference in Percentage of Participants","paramValue":"20.1","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"OR includes both CRR and partial renal response (PRR). CRR as defined in the primary outcome measure above. PRR defined as 50% improvement in urine protein:creatinine ratio, with one of following conditions met: 1. If baseline urine protein:creatinine ratio is ≤ 3.0, then urine protein:creatinine ratio of \\<1.0. 2. If baseline protein:creatinine ratio is \\> 3.0, then urine protein:creatinine ratio of \\<3.0, serum creatinine ≤15% above baseline value, and no urinary red cell casts and either RBCs/HPF ≤50% above baseline or \\<10 RBCs/HPF.","groups":[{"description":"Participants received obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"OG000","title":"OBINUTUZUMAB 1000MG and MMF"},{"description":"Participants received placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"OG001","title":"PLACEBO and MMF"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Modified intent-to-treat population will include all randomized participants who have received any amount of study drug. Participants who received an incorrect therapy were reported under the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"From baseline to Week 52","title":"Percentage of Participants Who Achieve Protocol Defined Overall Response (OR) at Week 52","type":"SECONDARY","unitOfMeasure":"Participants"}